In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes
Mike Grey doesn’t have any time to waste. Having regained control of two liver disease drugs from Shire and positioned them for pivotal studies — five years after first handing them off in a deal to sell Lumena, where he was CEO — Grey is steering Mirum straight into an IPO with a $86 million ask.
Not that Mirum has spent much of its $120 million Series A cash since launching last November. According to the S-1, the Californian biotech has burned through $23.3 million as of March, but expects expenses to pick up once their clinical work gathers steam.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.